gptkbp:instance_of
|
gptkb:pharmaceuticals
|
gptkbp:approves
|
gptkb:FDA
|
gptkbp:availability
|
prescription only
|
gptkbp:brand
|
gptkb:sofosbuvir
|
gptkbp:can_be_combined_with
|
gptkb:ledipasvir
gptkb:ribavirin
|
gptkbp:class
|
antiviral
|
gptkbp:clinical_trial
|
Phase 3
|
gptkbp:clinical_use
|
chronic hepatitis C genotype 1, 2, 3, 4, 5, 6
|
gptkbp:contraindication
|
severe liver disease
|
gptkbp:dosage_form
|
gptkb:tablet
|
gptkbp:drug_interactions
|
gptkb:phenytoin
gptkb:St._John's_Wort
gptkb:carbamazepine
gptkb:amiodarone
gptkb:rifampin
|
gptkbp:duration
|
12 weeks
24 weeks for certain genotypes
|
gptkbp:events
|
monitoring liver function
HCV RNA testing
|
gptkbp:financial_support
|
financial assistance programs
available through manufacturer
|
gptkbp:formulation
|
sofosbuvir 400 mg tablet
|
gptkbp:global_access
|
available in many countries
affordable generics in some regions
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sovaldi
|
gptkbp:ingredients
|
gptkb:sofosbuvir
|
gptkbp:invention
|
2028
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
gptkbp:marketed_as
|
gptkb:2013
|
gptkbp:mechanism_of_action
|
NS5 B polymerase inhibitor
|
gptkbp:patient_education
|
potential side effects
importance of adherence
|
gptkbp:patient_population
|
adults
pediatric patients
|
gptkbp:price
|
approximately $84,000 for a 12-week treatment
|
gptkbp:provides_guidance_on
|
recommended by AASLD
recommended by EASL
|
gptkbp:regulatory_compliance
|
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
|
gptkbp:research_focus
|
resistance testing
treatment of co-infections
long-term outcomes of treatment
new combinations with other antivirals
|
gptkbp:route_of_administration
|
oral
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
headache
hydration
nausea
insomnia
antiemetics
|
gptkbp:storage
|
room temperature
|
gptkbp:success_rate
|
over 90% for certain genotypes
|
gptkbp:treatment
|
chronic hepatitis C
|
gptkbp:used_for
|
treatment of hepatitis C
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences
|
gptkbp:bfsLayer
|
4
|